By targeting both VEGF-A and Ang-2, faricimab may offer a broader approach to the treatment of retinal diseases, potentially making it more effective than ranibizumab, which only targets VEGF-A [10, 16]. This evidence concerns the gene ANGPT2 and Abnormal retinal morphology.